Bioelectronic Devices Capture and Release Tumor Cells for Early Cancer Diagnosis
|
By LabMedica International staff writers Posted on 11 Sep 2023 |

Metastasis, the spread of cancer cells from the primary tumor to distant organs, is the main cause of cancer-related deaths. Metastasis occurs when a cancer cell detaches from the initial tumor, travels through the bloodstream and lymphatic system, and invades other parts of the body. Collecting these circulating tumor cells non-invasively is crucial for understanding cell biology, as well as for cancer diagnosis, prognosis, and drug development. Traditional methods for gathering these cells in a usable form are time-consuming, given that the concentration of these cells in the bloodstream is incredibly low compared to other cell types.
Now, a group of researchers at the University of the Basque Country (UPV/EHU, Leioa, Spain) has designed a bioelectronic device that could revolutionize this process. The device featuring gold electrodes coated with a smart polymer not only captures but also releases cells in a controllable, non-destructive manner, while simultaneously tracking these activities through standard electrical readings. This is seen as a foundational step toward creating universal systems for early cancer detection. Previous biosensors designed for this purpose were less than ideal because they damaged cells during the capture and release process. To address this, the team integrated smart materials with bioelectronics, which involves the use of carbon-based semiconductors, for more accurate and less harmful cell capture and release mechanisms.
In their preliminary tests, the researchers did not use real patient samples but instead relied on commercial cells sustained in culture media. The results demonstrated that the device successfully captured and released these cells. The team is now in the process of customizing the polymer to interact specifically with different types of cells. Currently, the device is being used on esophageal cancer patient samples. Its role is to selectively accumulate cancer cells, making it easier to determine their concentration in the sample.
“We wanted to come up with a device capable of concentrating cancer cells in order to detect their concentration,” said Janire Sáez, Ikerbasque research professor in the UPV/EHU’s Microfluidics Cluster Group. These are the first steps towards developing platforms for cancer screening. This could be a good step forward because they generally involve low-cost technologies and can be mass-produced. The idea is to use this type of technology for early cancer diagnosis.”
Related Links:
UPV/EHU
Latest Technology News
- AI Model Outperforms Clinicians in Rare Disease Detection
- AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
- Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
- AI-Powered Biomarker Predicts Liver Cancer Risk
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
Channels
Clinical Chemistry
view channelNew Blood Test Index Offers Earlier Detection of Liver Scarring
Metabolic fatty liver disease is highly prevalent and often silent, yet it can progress to fibrosis, cirrhosis, and liver failure. Current first-line blood test scores frequently return indeterminate results,... Read more
Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
Ovarian cancer is often diagnosed at a late stage because its symptoms are vague and resemble those of more common conditions. Unlike breast cancer, there is currently no reliable screening method, and... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read moreMicrobiology
view channel
Rapid Sequencing Could Transform Tuberculosis Care
Tuberculosis remains the world’s leading cause of death from a single infectious agent, responsible for more than one million deaths each year. Diagnosing and monitoring the disease can be slow because... Read more
Blood-Based Viral Signature Identified in Crohn’s Disease
Crohn’s disease is a chronic inflammatory intestinal disorder affecting approximately 0.4% of the European population, with symptoms and progression that vary widely. Although viral components of the microbiome... Read morePathology
view channel
Novel mcPCR Technology to Transform Testing of Clinical Samples
DNA methylation is an important biological marker used in the diagnosis and monitoring of many diseases, including cancer. These chemical modifications to DNA influence gene activity and can reveal early... Read more
Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
Sex differences in Alzheimer’s disease present ongoing diagnostic challenges, with women often experiencing a disproportionate disease burden even when preclinical amyloid-beta levels are similar to men.... Read moreTechnology
view channel
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more







